April 24, 2024

Cidara Therapeutics: Cidara Therapeutics reacquires global rights to CD388 from Johnson & Johnson, announces financing of 240 million USD, will proceed with CD388 phase 2b study in autumn 2024

By admin | 24 Apr, 24 |

Cidara Therapeutics (...) today announced that it has entered into

Cidara Therapeutics: Divestiture of rezafungin to focus on Cloudbreak DFC pipeline, including CD388

By admin | 24 Apr, 24 |

https://www.cidara.com/news/cidara-therapeutics-announces-divestiture-of-rezafungin-to-mundipharma-to-focus-on-advancing-the-clinical-development-of-cloudbreak-dfc-pipeline

CureVac/GSK: Start of combined phase 1/2 study for avian influenza (H5N1) mRNA vaccine

By admin | 24 Apr, 24 |

Contact

Menu

About